tranont glp-1 How Activate Supports Natural Production & Metabolism GLP-1 receptor agonists for individualized
Description
Drawing from PSGs 2025 Trends in Drug Benefit Design Report, this webinar provides essential insights for benefits professionals navigating the complex landscape of GLP-1 coverage decisions
In China, domestic companies are closely aligning with these global trends, and leading players are actively advancing in this direction
3 GI tolerability appears competitive Vomiting rates: 2.4% (10 mg) 11.4% (25 mg) 7.5% (50 mg) This compares favorably with published vomiting rates of 31% (Novo) and 1432% (Lilly), depending on dose
each column is a target dose per injection
doi: 10.1089/thy.2007.0223
